Scientists and medical teams are gaining new insights into the rare Bundibugyo strain of Ebola as a devastating outbreak in the Democratic Republic of Congo (DRC) continues to spread, raising concerns about delayed diagnosis, high mortality rates among children and the lack of approved vaccines or treatments.
The outbreak has recorded more than 11,000 cases and over 5,500 deaths, with the virus spreading at twice the pace of the 2014-2016 Ebola epidemic in West Africa, the largest on record.
Researchers are investigating the characteristics of the Bundibugyo virus to better understand its transmission and identify effective ways to contain it. However, experts have warned that the humanitarian crisis in eastern Congo, where the outbreak is concentrated, is complicating the collection of reliable data.
“There are so many different factors to compare across outbreaks, even within outbreaks, it is really hard,” said Daniel Bausch, a member of the World Health Organization’s Ebola emergency committee and visiting professor at the Geneva Graduate Institute.
WHO Ebola incident manager Catherine Smallwood said teams were gathering evidence to improve the response to the outbreak.
” Soon we’ll be able to make some bold statements about what’s the same, what’s different, and what we need to adjust,” she said.
Bleeding less common among patients
One of the main findings concerns the symptoms associated with the Bundibugyo strain, particularly among children.
Ebola typically causes fever, vomiting and diarrhoea, with severe cases sometimes involving internal and external bleeding. However, bleeding has been reported in only around 5 to 10 per cent of confirmed cases in the current outbreak, according to Yap Boum, Africa Centres for Disease Control and Prevention deputy Ebola incident manager.
The symptom is less common than in outbreaks involving the Zaire strain, potentially making Bundibugyo more difficult to distinguish from other illnesses, including malaria.
The difficulty in diagnosing the virus, combined with early testing challenges, may have contributed to the delayed identification of the outbreak. Tests designed for other Ebola strains do not detect Bundibugyo.
Around 70 per cent of patients are still dying in their communities rather than healthcare facilities, complicating efforts to monitor transmission. The WHO and Africa CDC believe the virus may have been spreading for months before the outbreak was officially declared in May.
Children face higher mortality
Children under five have been particularly affected, with 1,207 confirmed cases and 844 deaths, according to figures from the Congolese health ministry and WHO. The fatality rate among young children is approximately 70 per cent, compared with around 50 per cent among adults.
WHO officials said gastrointestinal symptoms are more common in young children than fever, making early diagnosis and treatment more difficult.
Although the mortality rate is higher than in previous Bundibugyo outbreaks, it remains below the levels associated with some other Ebola strains, including Zaire, which can have fatality rates of up to 80 per cent without treatment.
Vaccines and treatments under investigation
Researchers are also studying the long-term effects of infection and the prevalence of milder cases. Around 700 survivors have enrolled in research and support programmes, according to the WHO.
Genomic sequencing has found differences between Bundibugyo and more common Ebola strains, but researchers have not identified evidence that the virus is rapidly evolving or becoming more transmissible.
A trial is examining whether Merck’s Ervebo vaccine, developed against the Zaire strain, could provide protection against Bundibugyo. Vaccines specifically designed for the strain are also expected to enter trials, while antiviral drugs from Gilead Sciences and Mapp Biopharmaceutical are being tested in Congo.
Experts say isolating patients and other established containment measures have helped control transmission in some early hotspots.
Yap Boum said evidence that vaccines or treatments could offer protection would significantly change the response to the outbreak, which currently has no licensed medical interventions specifically targeting Bundibugyo.

Facebook
Twitter
Instagram
LinkedIn
RSS